Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion

Table 1 Transcatheter arterial chemoembolization approved as an adjuvant therapy for hepatocellular carcinoma patients with microvascular invasion

Ref.	Study type	Adjuvant therapy	Number	2-yr DFS (%)	P value	2-yr OS (%)	P value	PMID
Li et al[17]	RCT	HAIC	63	58.7	0.023	97.7	0.037	32418078
		NAT	64	38.6		78.5
Sun et al[72]	Retrospective	TACE	137	55.5	0.012	78.8	0.006	26714945
		NAT	185	36.2		62.2
Wei et al[73]	RCT	TACE	125	44.7	0.02	64.3	0.029	30305149
		NAT	125	30.6		49.8
Ye et al[13]	Retrospective	TACE	86	58.3	0.002	86.5	0.019	29151695
		NAT	174	41.1		65.7
Liu et al[74]	Retrospective	TACE	24	26.9	0.03	NA	NA	27038790
		NAT	26	4.2		NA
Wang et al[75]	Retrospective	TACE	57	66	0.008	94	0.04	30249510
		NAT	57	50		83
Cai et al[76]	Retrospective	TACE	25	39.1	0.06	NA	NA	34926296
		TACE + T cell self	23	58.2		NA
Kim et al[27]	RCT	HAIC	31	9.1	0.324	87.1	0.561	22067673
		NAT	62	4.2		78.3
Nitta et al[77]	Retrospective	HAIC	38	33.1		56.2	0.318	23435678

DFS: Disease-free survival; OS: Overall survival; TACE: Transcatheter arterial chemoembolization; HAIC: Hepatic arterial infusion chemotherapy; NAT: No adjuvant therapy; NA: Not available; RCT: Randomized clinical trial.